P14.69 Trends in postoperative chemoradiotherapy for Glioblastoma patients: a Danish cohort study

2021 ◽  
Vol 23 (Supplement_2) ◽  
pp. ii51-ii51
Author(s):  
A K Trip ◽  
V K Veluppillai ◽  
R H Dahlrot ◽  
T L Guldberg ◽  
A Muhic ◽  
...  
Keyword(s):  
Cohort Study ◽  
Real World ◽  
Performance Status ◽  
Concomitant Treatment ◽  
University Hospitals ◽  
Pronounced Increase ◽  
Evidence Based Treatments ◽  
Extent Of Surgery ◽  
Danish Cohort ◽  
Over Time

Abstract BACKGROUND Postoperative chemoradiotherapy (CRT), using conventional radiotherapy (convRT), has a key role in the treatment of glioblastoma (GBM) supported by level 1A evidence. In the past decade, evidence supporting hypofractionated radiotherapy (HFRT) has emerged. However, GBM patients in clinical trials are highly selected. Consequently, real-world patients may not be able to undergo evidence-based treatments. The aim of this retrospective Danish cohort study was to evaluate the utilisation of and compliance with postoperative CRT in real-world GBM patients over time. MATERIAL AND METHODS All adults (≥18 years) with newly diagnosed GBM (histology confirmed) between 2011 and 2018 were identified via the Danish Neuro-Oncology Registry, which was furthermore used to extract all data. Radiotherapy (RT) was classified as convRT (≤2 Gy/fr, planned dose 44–66 Gy) or HFRT (>2 Gy/fr, planned dose 34 or 40 Gy). The utilisation of and compliance with CRT (only concomitant treatment assessed) was measured by intended and administered treatment, respectively. To assess trends, patients were grouped per year of diagnosis. Multivariable logistic regression was used to analyse the association of age (</≥70), sex, performance status (PS) before surgery and RT, tumour focality, extent of surgery, concomitant chemotherapy (CT), hospital (4 University Hospitals), and year of diagnosis, with convRT or HFRT. RESULTS The cohort consisted of 2153 patients. For the entire period, postoperative RT was planned in 1743 patients: utilisation of 81%, over time fluctuating between 77 and 84%. ConvRT was planned in 1428 patients (66%), with a steadily decreasing utilisation from 73% in 2011 to 52% in 2018. Of those, 1346 (94%) could complete RT as planned (over time fluctuating between 88–97%). In this group, the utilisation of and compliance with concomitant CT was 86% (fluctuating between 80–93%) and 73% (fluctuating between 47–84%), respectively. HFRT was planned in 315 patients (15%), with a utilisation of up to 26% in 2018, after a more pronounced increase since 2014. The compliance with HFRT was 93%, fluctuating between 85–100%. In this group, the utilisation of and compliance with concomitant CT was 33% (fluctuating between 0–47%) and 78% (fluctuating between 33–100%), respectively. The utilisation of HFRT compared to convRT was significantly associated with higher age, poorer PS before RT, multifocal tumour, less extensive surgery, less frequent concomitant CT, one hospital of RT treatment, and more recent diagnosis years. CONCLUSION The increased utilisation of HFRT is in line with emerging evidence during the cohort period. However, while HFRT was developed as a more convenient schedule for those with a poorer PS and older age, the overall utilisation of postoperative RT did not increase. Nor did the compliance with CRT increase in real-world Danish GBM patients.

scholarly journals Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study

2020 ◽  
Vol 8 (1) ◽  
pp. 68-76
Author(s):  
Sandra Bohn Thomsen ◽  
Kristine Højgaard Allin ◽  
Johan Burisch ◽  
Camilla Bjørn Jensen ◽  
Susanne Hansen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cohort Study ◽  
Bowel Disease ◽  
Concomitant Treatment ◽  
Inflammatory Bowel ◽  
Danish Cohort

Chemotherapy at the end of life in colorectal and pancreatic cancer: Real-world data and trends over time.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18723-e18723
Author(s):  
Catherine Dunn ◽  
Belinda Lee ◽  
Jeremy David Shapiro ◽  
Rachel Wong ◽  
Grace Gard ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
End Of Life ◽  
Real World ◽  
Performance Status ◽  
Univariate Analysis ◽  
Locally Advanced ◽  
Chemotherapeutic Regimen ◽  
Trends Over Time ◽  
Line Of Therapy ◽  
Over Time

e18723 Background: Chemotherapy at the end of life (CEOL) is widely accepted as an indicator of aggressive care. However, the evidence is limited primarily to single-centre experiences, with no consensus regarding acceptable benchmarks for CEOL, nor how this may be changing over time and with novel treatment options. We describe ‘real world’ CEOL in two large, multisite Australian registries of metastatic colorectal cancer (mCRC) and both locally advanced and metastatic pancreatic cancer (PC). Methods: Data was analysed from the TRACC and PURPLE registries, two large prospective multisite Australian cancer registries collecting prospective demographic, tumour, treatment and outcome data for mCRC and PC respectively. We identified all decedents between May 2009 and November 2020, determined the proportion who died within 14 or 30 days of chemotherapy (14D / 30D), or within 30D after a new line of therapy, defined as the first cycle of a new treatment regimen. Using univariate analysis, we compared baseline demographic and clinicopathological variables and trends over time. Results: 1505 mCRC and 602 PC decedents were identified. 20.9% of decedents (21.6% mCRC and 19.3% PC) received chemotherapy within 30D, and 11.5% within 14D (12.3% mCRC and 9.6% PC). There were lower rates of 30D CEOL after the first cycle of a new line of therapy (4.3% mCRC and 5.7% PC). Rates of CEOL decreased over the study period for mCRC (median rate of initial 3-year period 28% versus 15% in last 3-year period), but remained largely static for PC (18.9% versus 17.9%). 30D CEOL was more likely with palliative than curative intent treatment (mCRC OR 1.6, 95% CI 1.14-2.25, p = 0.007, PC OR 5.3, 95% CI 1.6-17.8), and advanced rather than local disease in PC (PC OR 2.59, 95%CI 1.6-4.1, p < 0.001). There was a trend towards CEOL and poorer performance status (ECOG) across all groups, only significant for 30D CEOL mCRC (OR 1.51, 95% CI 1.04-2.2). There was no association between CEOL and patient age, gender, Charlson comorbidity score or lines of therapy. Conclusions: Real-world rates of CEOL are higher in our cohorts of mCRC and PC patients than historical benchmarks but comparable to contemporary reports, which may be due to a wider array of available active treatments. Overall rates are decreasing over time for mCRC but static for PC, which may reflect the poorer overall survival for PC and lack of new effective therapies. The lower rates of death after new lines of therapy may signify that CEOL is more likely with existing treatment regimens and that clinicians are less likely to initiate a new chemotherapeutic regimen at EOL.

scholarly journals Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study

2020 ◽  
Vol 7 (8) ◽  
Author(s):  
Bernd Schulte ◽  
Christiane S Schmidt ◽  
Jakob Manthey ◽  
Lisa Strada ◽  
Stefan Christensen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hepatitis C ◽  
Real World ◽  
Patient Reported Outcomes ◽  
Direct Acting Antivirals ◽  
Hcv Treatment ◽  
Opioid Agonist ◽  
Patient Reported ◽  
Direct Acting ◽  
Over Time

Abstract Background Patient-reported outcomes (PROs) can help to reduce uncertainties about hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) among people who inject drugs and increase treatment uptake in this high-risk group. Besides clinical data, this study analyzed for the first time PROs in a real-world sample of patients on opioid agonist treatment (OAT) and HCV treatment with DAAs. Methods HCV treatment data including virological response, adherence, safety, and PROs of 328 German patients on OAT were analyzed in a pragmatic prospective cohort study conducted from 2016 to 2018. Clinical effectiveness was defined as sustained virological response (SVR) at week 12 after end of treatment and calculated in per-protocol (PP) and intention-to-treat (ITT) analyses. Changes over time in PROs on health-related quality of life, physical and mental health, functioning, medication tolerability, fatigue, concentration, and memory were analyzed by repeated-measures analyses of variances (ANOVAs). Results We found high adherence and treatment completion rates, a low number of mainly mild adverse events, and high SVR rates (PP: 97.5% [n = 285]; ITT: 84.5% [n = 328]). Missing SVR data in the ITT sample were mainly caused by patients lost to follow-up after treatment completion. Most PROs showed statistically significant but modest improvements over time, with more pronounced improvements in highly impaired patients. Conclusions This real-world study confirms that DAA treatment among OAT patients is feasible, safe, and effective. PROs show that all patients, but particularly those with higher somatic, mental, and social burden, benefit from DAA treatment.

scholarly journals Drug‐drug interaction between warfarin and statins: A Danish cohort study

2020 ◽  
Author(s):  
Anna E. Engell ◽  
Andreas L.O. Svendsen ◽  
Bent S. Lind ◽  
Christen L. Andersen ◽  
John S. Andersen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Drug Interaction ◽  
Danish Cohort ◽  
Drug Drug Interaction

scholarly journals 325 - Relationship quality in dementia: Preliminary longitudinal analyses of the EU-JPND Actifcare cohort study

2020 ◽  
Vol 32 (S1) ◽  
pp. 83-83
Author(s):  
Maria J. Marques ◽  
Bob Woods ◽  
Eva Y.L. Tan ◽  
Marjolein de Vugt ◽  
Frans Verhey ◽  
...  
Keyword(s):  
Social Support ◽  
Cohort Study ◽  
Relationship Quality ◽  
Sense Of Coherence ◽  
Unmet Needs ◽  
Neuropsychiatric Symptoms ◽  
Longitudinal Analyses ◽  
Family Carers ◽  
Over Time

INTRODUCTIONRelationship quality (RQ) in dyads of persons with dementia and their family carers is important both as a clinical outcome and as a determinant of health and quality of life. In previous work we studied RQ using baseline data of a large-scale European longitudinal study on timely access to and use of community formal services in dementia (EU-JPND Acticare). We concluded that neuropsychiatric symptoms and carer stress contributed to discrepancies in RQ ratings within the dyad, which were less favourable when reported by family carers. This and other associations (e.g. between carer-rated RQ and sense of coherence) were cautiously interpreted, in the context of a cross-sectional analysis.OBJECTIVESTo analyse how carer-reported RQ varies over time and to examine its most important influencing factors.METHODSWe present preliminary longitudinal analyses from the Actifcare cohort study of 451 community-dwelling persons with dementia and their primary carers in eight European countries (12-month follow-up). Comprehensive assessments included the Positive Affect Index (PAI) to assess RQ, persons with dementia’s neuropsychiatric symptoms, persons with dementia and carers’ unmet needs, carers’ anxiety and depression, social support, sense of coherence and stress.RESULTSCarers’ mean PAI scores decreased over the 12 -month period. The person with dementia neuropsychiatric symptoms and unmet needs, and carers’ perceived social support were significant predictors of carers’ RQ change.DISCUSSION AND CONCLUSIONWe analysed carer-reported RQ variation over time and predictors in a large European sample of persons with dementia and their family carers. As expected, RQ decreased over the oneyear follow-up period as the disease progressed. Its main predictors in this sample (neuropsychiatric symptoms and the person’s unmet needs, together with carers’ social support) can all influence the impact that caregiving has on the carer and on how time and energy-consuming caregiving is. The role of increased clinical symptoms (also affecting communication difficulties), together with carers’ exhaustion, must be equated. Overall, these results may help us to tailor interventions addressing RQ and potentially improve dementia outcomes.

scholarly journals Prevalence and Course of IgA and IgG Antibodies against SARS-CoV-2 in Healthcare Workers during the First Wave of the COVID-19 Outbreak in Germany: Interim Results from an Ongoing Observational Cohort Study

Healthcare ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 498
Author(s):  
Mark Reinwald ◽  
Peter Markus Deckert ◽  
Oliver Ritter ◽  
Henrike Andresen ◽  
Andreas G. Schreyer ◽  
...  
Keyword(s):  
Cohort Study ◽  
Healthcare Workers ◽  
Significant Proportion ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Observational Cohort Study ◽  
Igg Antibodies ◽  
University Hospitals ◽  
Observational Cohort

(1) Background: Healthcare workers (HCWs) are prone to intensified exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the ongoing pandemic. We prospectively analyzed the prevalence of antibodies against SARS-CoV-2 in HCWs at baseline and follow up with regard to clinical signs and symptoms in two university hospitals in Brandenburg, Germany. (2) Methods: Screening for anti-SARS-CoV-2 IgA and IgG antibodies was offered to HCWs at baseline and follow up two months thereafter in two hospitals of Brandenburg Medical School during the first wave of the COVID-19 pandemic in Germany in an ongoing observational cohort study. Medical history and signs and symptoms were recorded by questionnaires and analyzed. (3) Results: Baseline seroprevalence of anti-SARS-CoV-2 IgA was 11.7% and increased to 15% at follow up, whereas IgG seropositivity was 2.1% at baseline and 2.2% at follow up. The rate of asymptomatic seropositive cases was 39.5%. Symptoms were not associated with general seropositivity for anti-SARS-CoV-2; however, class switch from IgA to IgG was associated with increased symptom burden. (4) Conclusions: The seroprevalence of antibodies against SARS-CoV-2 was low in HCWs but higher compared to population data and increased over time. Screening for antibodies detected a significant proportion of seropositive participants cases without symptoms.

Sign in / Sign up

Export Citation Format

Share Document